{"entity":{"id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of HLA-G-CAR.BiTE allogeneic γδ T cells in advanced solid tumours, run by Ever Supreme Bio Technology Co., Ltd., now recruiting.","summary":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT06150885 by Ever Supreme Bio Technology Co., Ltd., with 60 participants planned, started 2024-09-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: HLA-G-CAR.BiTE allogeneic γδ T cells.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06150885","url":"https://clinicaltrials.gov/study/NCT06150885"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06150885","phase":"1/2","setting":"A Single Arm, Open Label, Dose-escalation Phase I and Dose-expansion Phase IIa Clinical Study to Evaluate the Feasibility, Safety, and Efficacy of Allogeneic Chimeric Antigen Receptor (CAR) Gamma-Delta T Cells CAR001 in Subjects With Relapsed/Refractory Solid Tumors","sponsor":"Ever Supreme Bio Technology Co., Ltd.","enrolled":60,"outcomes":[]},"route":"/trials/nct06150885/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}